Sichuan Shuangma Expands CDMO Operations Into Major Western Markets, Secures Partnerships With Multiple US and European Biotech Firms

Deep News

昨天

On September 15, Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) published its investor relations activity record, highlighting a significant milestone.

According to the filing, the company's CDMO business has successfully penetrated mainstream markets in the United States and Europe, establishing collaborations with several well-known biotechnology companies across both regions.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1181425093"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181425093\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181425093?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181425093","market":"sh","top_or_hot":-1,"title":"Sichuan Shuangma Expands CDMO Operations Into Major Western Markets, Secures Partnerships With Multiple US and European Biotech Firms","media":"Deep News","content":"<p>On September 15, <b>Sichuan Hexie Shuangma Co., Ltd. (000935.SZ)</b> published its investor relations activity record, highlighting a significant milestone.<br><br>According to the filing, the company's CDMO business has successfully penetrated mainstream markets in the United States and Europe, establishing collaborations with several well-known biotechnology companies across both regions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Shuangma Expands CDMO Operations Into Major Western Markets, Secures Partnerships With Multiple US and European Biotech Firms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Shuangma Expands CDMO Operations Into Major Western Markets, Secures Partnerships With Multiple US and European Biotech Firms\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-09-15 22:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On September 15, <b>Sichuan Hexie Shuangma Co., Ltd. (000935.SZ)</b> published its investor relations activity record, highlighting a significant milestone.<br><br>According to the filing, the company's CDMO business has successfully penetrated mainstream markets in the United States and Europe, establishing collaborations with several well-known biotechnology companies across both regions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1181425093","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181425093","pubTimestamp":1789484132,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On September 15, Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) published its investor relations activity record, highlighting a significant milestone.According to the filing, the company's CDMO...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159837":"生物科技","BK4139":"生物科技","IEIH":"iShares Evolved U.S. Innovative Healthcare ETF","CDMO":"Avid Bioservices, Inc.","000935":"四川双马","AGNG":"Global X Aging Population ETF","MEDX":"HORIZON KINETICS MEDICAL ETF","BK4588":"碎股","LNGR":"Global X Longevity Thematic ETF","BK0021":"外资并购(国际板)","BK0028":"国家队","GDOC":"Goldman Sachs Future Health Care Equity ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","XBI":"SPDR S&P Biotech ETF","BK0004":"股权转让","BK4581":"高盛持仓","SYNB":"PUTNAM BIOREVOLUTION ETF","BK0235":"非金矿物","BK4585":"ETF&股票定投概念"},"translate_title":"四川双马将CDMO业务拓展至西方主要市场，与多家美国和欧洲生物技术公司建立合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159837":1,"MEDX":1,"IBBJ":1,"IEIH":1,"CDMO":1,"HBImain":1,"XBI":1,"LNGR":1,"000935":1,"SYNB":1,"AGNG":1,"GDOC":1},"content_text":"On September 15, Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) published its investor relations activity record, highlighting a significant milestone.According to the filing, the company's CDMO business has successfully penetrated mainstream markets in the United States and Europe, establishing collaborations with several well-known biotechnology companies across both regions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}